NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

20/20 GeneSystems Utilizes Continuous Machine Learning to Aid in Early Detection of Cancer

“20/20 Hindsight” Platform Improves Accuracy of Most Widely Used Cancer Biomarkers 20/20 GeneSystems, Inc. is a Rockville, MD-based, digital diagnostics company focused on reducing cancer mortality through early detection.  20/20 GeneSystems is pioneering a novel approach to cancer detection, called “20/20 Hindsight”, that uses continuous machine learning to utilize large patient data sets of biomarker values to evaluate clinical factors such as age, gender, and smoking history for early cancer detection.  20/20 GeneSystems’ “20/20 Hindsight” platform can aid in the early detection of cancer by improving the accuracy of the most widely used cancer biomarkers. 20/20 GeneSystems was founded in 2000 to develop and commercialize innovative, proprietary diagnostics tests that aid in the fight against cancer. The tests generally fall into three categories: early detection of lung cancer, using “PAULA’s Test” for persons with high risk of cancer due to long-term smoking exposure; multi-cancer blood testing, using 20/20 GeneSystems’ “OneTEST”, which screens for several otherwise deadly cancers at earlier, treatable stages when they can be surgically removed; and diagnostics for biological threat detection, which are conducted by 20/20 GeneSystems’ “BioCheck”, a field screening test for emergency responders and security personnel to test unknown suspicious powders. 20/20 GeneSystems collaborates extensively with the National Institutes of Health, and recently has been strongly focused on bringing its technology to Asian markets.  Most recently, in January 2018, 20/20 GeneSystems completed its first equity crowdfunding campaign, raising $1.07 million, the maximum amount permitted under current SEC rules.  Funds from the campaign are being used to expedite the final development of “OneTEST” for multi-cancer blood testing.  20/20 GeneSystems is also initiating a second equity crowdfunding campaign under Reg A+, in order to raise capital from both accredited and non-accredited investors.  Prior to the crowdfunding campaigns, 20/20 has raised Series A and venture funding.  The company is backed by the Maryland Venture Fund, Keiretsu Forum Northwest, Keiretsu Capital, Ping An Ventures, and Dean Bartosh, among others. In upcoming news, 20/20 GeneSystems is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City.  Learn more and register to attend the conference at www.nyconcologyconference.com.

To continue reading, please Login or Join